JPMorgan has increased its price target for Eli Lilly stock to $1,150 from $1,050, while reiterating an "Overweight" rating. The updated forecast came after meetings between JPMorgan analysts and Eli Lilly's management team, including the CEO and CFO. The investment bank's positive outlook is based on continued U.S. market share gains for the company's incretin portfolio, which includes its highly successful weight loss and diabetes medications. JPMorgan anticipates significant growth for Eli Lilly in 2026 and beyond, highlighting the large and expanding international market for obesity treatments as a key catalyst.